Speeding the flow toward personalized therapy in childhood acute leukemia

Pediatric Blood and Cancer

Volumn 53, Issue 4, 2009, Pages 525-526

  Simonds, Erin F ^a   Davis, Kara L ^a   Lacayo, Norman J ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ASPARAGINASE; CELL MARKER; GLUCOCORTICOID; JANUS KINASE 2; LIPOCORTIN 5; PREDNISOLONE; PROTEIN BCL 2; PROTEIN BCL XL; SIGNAL PEPTIDE; STAT5 PROTEIN; VINCRISTINE;

ACUTE LYMPHOBLASTIC LEUKEMIA; AUTOPHAGY; BLAST CELL; BONE MARROW BIOPSY; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER RESISTANCE; CANCER SURVIVAL; CELL DEATH; CELL HETEROGENEITY; CHEMOSENSITIVITY; CHILD; CHILDHOOD CANCER; DISEASE FREE SURVIVAL; DRUG SENSITIVITY; FLOW CYTOMETRY; HUMAN; IN VITRO STUDY; LEUKEMIA CELL; LYMPHOCYTE SUBPOPULATION; PRIORITY JOURNAL; SHORT SURVEY; APOPTOSIS; DRUG EFFECT; METHODOLOGY; NOTE;

APOPTOSIS; CHILD; FLOW CYTOMETRY; HUMANS; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA;

EID: 69849092349     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.22180     Document Type: Short Survey

References (11)

1. Harned TM, Gaynon P. Relapsed acute lymphoblastic leukemia: Current status and future opportunities. Curr Oncol Rep 2008;10:453-458.
2. Borowitz MJ, Devidas M, Hunger SP. et al. Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia and its relationship to other prognostic factors: A Children's Oncology Group Study. Blood 2008;111:5477-5485.
3. Campana D. Minimal residual disease in acute lymphoblastic leukemia. Semin Hematol 2009;46:100-106.
4. Mosmann T. Rapid colorimetric assay for cellular growth and survival: Application to proliferation and cytotoxicity assays. J Immunol Methods 1983;65:55-63. (Pubitemid 14203433)
5. Nygren P, Kristensen J, Jonsson B, et al. Feasibility of the fluorometric microculture cytotoxicity assay (FMCA) for cytotoxic drug sensitivity testing of tumor cells from patients with acute lymphoblastic leukemia. Leukemia 1992;6:1121-1128.
6. Lönnerholm G, Thörn I, Sundström C, et al. In vitro cellular drug sensitivity at diagnosis is correlated to minimal residual disease at end of induction therapy in childhood acute lymphoblastic leukemia. Leuk Res 2009;33:46-53.
7. Kaspers GJ, Pieters R, Van Zantwijk CH, et al. Prednisolone resistance in childhood acute lymphoblastic leukemia: Vitro-vivo correlations and cross-resistance to other drugs. Blood 1998;92:259-266. (Pubitemid 28303201)
8. Den Boer ML, Harms DO, Pieters R, et al. Patient stratification based on prednisolone-vincristine-asparaginase resistance profiles in children with acute lymphoblastic leukemia. J Clin Oncol 2003;21:3262-3268. (Pubitemid 46606259)
9. Irish JM, Hovland R, Krutzik PO, et al. Single cell profiling of potentiated phospho-protein networks in cancer cells. Cell 2004;118:217-228. (Pubitemid 38962577)
10. Mullighan CG, Phillips LA, Su X, et al. Genomic analysis of the clonal origins of relapsed acute lymphoblastic leukemia. Science 2008;322:1377-1380. (Pubitemid 352775249)
11. Laane E, Tamm KP, Buentke E, et al. Cell death induced by dexamethasone in lymphoid leukemia is mediated through initiation of autophagy. Cell Death Differ 2009;16:1018-1029.